This inventor holds 1 USPTO granted patent. Top assignee: Japan Chemical Research Co., Ltd.. Active years: 1992.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1992
Title: Innovations by Jun Tateishi in Virus Removal Technology
Introduction
Jun Tateishi is an accomplished inventor based in Fukuoka, Japan. He has made significant contributions to the field of biotechnology, particularly in the area of virus removal from physiologically active solutions. His innovative approach has the potential to enhance the safety and efficacy of various biological substances.
Latest Patents
Jun Tateishi holds a patent for a process designed to remove viruses from solutions containing physiologically active substances. The patent describes a membrane filter with a pore size ranging from 0.025 to 0.05 micrometers. This filter is treated by passing a solution of water-soluble high molecular substances, such as albumin, dextran, polyvinylpyrrolidone, polysorbate 80, or gelatin, through it. The treated filter allows for the high recovery rate of active substances, such as human growth hormone and epidermal growth factor, while effectively removing harmful viruses, including the pathogen responsible for Creutzfeldt-Jacob disease.
Career Highlights
Jun Tateishi is associated with Japan Chemical Research Co., Ltd., where he continues to develop innovative solutions in the field of biotechnology. His work has garnered attention for its practical applications in improving the safety of biologically active substances.
Collaborations
Throughout his career, Jun has collaborated with notable colleagues, including Tetsuyuki Kitamoto and Hajime Hiratani. These collaborations have contributed to the advancement of research and development in their respective fields.
Conclusion
Jun Tateishi's innovative work in virus removal technology represents a significant advancement in biotechnology. His patented process not only enhances the safety of physiologically active substances but also showcases the importance of innovation in addressing critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile